Julia M Lappin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/452733/publications.pdf

Version: 2024-02-01

121 papers 4,992 citations

38 h-index 65 g-index

125 all docs 125 docs citations

125 times ranked

6584 citing authors

#	Article	IF	CITATIONS
1	Rethinking the course of psychotic disorders: modelling long-term symptom trajectories. Psychological Medicine, 2022, 52, 2641-2650.	4.5	11
2	The health service contact patterns of people with psychotic and non-psychotic forms of severe mental illness in New South Wales, Australia: A record-linkage study. Australian and New Zealand Journal of Psychiatry, 2022, 56, 675-685.	2.3	3
3	Characteristics of fatal gabapentinoid-related poisoning in Australia, 2000–2020. Clinical Toxicology, 2022, 60, 304-310.	1.9	5
4	Characteristics of fatal â€~novel' benzodiazepine toxicity in Australia. Forensic Science International, 2022, 331, 111140.	2.2	14
5	A pilot study of a mindfulness informed yoga intervention in young people with psychosis. Microbial Biotechnology, 2022, 16, 1036-1042.	1.7	4
6	Characteristics of fatal â€~novel' synthetic opioid toxicity in Australia. Drug and Alcohol Dependence, 2022, 232, 109292.	3.2	8
7	Characteristics of fatal tapentadolâ€related toxicity in Australia. Drug and Alcohol Review, 2022, , .	2.1	2
8	Comorbid substance use in psychosis: Someone else's problem?. Australian and New Zealand Journal of Psychiatry, 2022, 56, 5-7.	2.3	1
9	Detection and intervention in emerging youth mental health issues: Outcomes from the first year of the CASPAR service. Microbial Biotechnology, 2021, 15, 167-173.	1.7	3
10	Characteristics and circumstances of death related to the selfâ€administration of ketamine. Addiction, 2021, 116, 339-345.	3.3	9
11	Neurological Signs at the First Psychotic Episode as Correlates of Long-Term Outcome: Results From the AESOP-10 Study. Schizophrenia Bulletin, 2021, 47, 118-127.	4.3	20
12	Trends and characteristics in barbiturate deaths Australia 2000–2019: a national retrospective study. Clinical Toxicology, 2021, 59, 224-230.	1.9	6
13	Diagnostic stability and outcome after first episode psychosis. Journal of Mental Health, 2021, 30, 104-112.	1.9	9
14	Scoping Review of Family Interventions That Support the Physical Health of Caregivers. Research on Social Work Practice, 2021, 31, 234-243.	1.9	1
15	Characteristics and circumstances of death related to buprenorphine toxicity in Australia. Drug and Alcohol Dependence, 2021, 218, 108360.	3.2	7
16	Cognitive improvement among abstinent methamphetamine users: A 2â€year prospective longitudinal study. American Journal on Addictions, 2021, 30, 543-551.	1.4	1
17	Increased barbiturate deaths: an unintended consequence of increased publicity for methods of doâ€itâ€yourself euthanasia?. Addiction, 2021, 116, 3273-3275.	3.3	O
18	Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review. Experimental Neurology, 2021, 343, 113793.	4.1	13

#	Article	IF	CITATIONS
19	â€~Synthetic cannabis': A dangerous misnomer. International Journal of Drug Policy, 2021, 98, 103396.	3.3	13
20	â€To the Arabic Community Disability Is Not Normal': Multiple Stakeholder Perceptions of the Understandings of Disability among Iraqi and Syrian People from Refugee Backgrounds. Journal of Refugee Studies, 2021, 34, 2849-2870.	1.7	7
21	Barbiturateâ€related hospitalisations, drug treatment episodes, and deaths in Australia, 2000‒2018. Medical Journal of Australia, 2021, , .	1.7	1
22	Clinical Management of Withdrawal Series. Addiction, 2021, , .	3.3	0
23	Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin, 2020, 46, 505-516.	4.3	79
24	Characteristics and circumstances of synthetic cannabinoid-related death. Clinical Toxicology, 2020, 58, 368-374.	1.9	50
25	Symptom remission at 12-weeks strongly predicts long-term recovery from the first episode of psychosis. Psychological Medicine, 2020, 50, 1452-1462.	4.5	16
26	MDMA-related deaths in Australia 2000 to 2018. International Journal of Drug Policy, 2020, 76, 102630.	3.3	24
27	Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies. Molecular Psychiatry, 2020, 25, 1487-1499.	7.9	339
28	Women and Stigma: A Protocol for Understanding Intersections of Experience through Body Mapping. International Journal of Environmental Research and Public Health, 2020, 17, 5432.	2.6	17
29	Global prevalence and burden of HIV-associated neurocognitive disorder. Neurology, 2020, 95, e2610-e2621.	1.1	172
30	Prevalence and correlates of food insecurity in community-based individuals with severe mental illness receiving long-acting injectable antipsychotic treatment. British Journal of Nutrition, 2020, 124, 470-477.	2.3	10
31	Prevalence and Characteristics Associated with Chronic Noncancer Pain in Suicide Decedents: A National Study. Suicide and Life-Threatening Behavior, 2020, 50, 778-791.	1.9	11
32	Characteristics and circumstances of death related to gamma hydroxybutyrate (GHB). Clinical Toxicology, 2020, 58, 1028-1033.	1.9	17
33	Targeted Intervention to Reduce Smoking among People with Severe Mental Illness: Implementation of a Smoking Cessation Intervention in an Inpatient Mental Health Setting. Medicina (Lithuania), 2020, 56, 204.	2.0	4
34	Exploring the intersection of human rights, health, disability and refugee status: an arts-based approach. Australian Journal of Human Rights, 2020, 26, 387-404.	0.6	8
35	Ambient fine particulate matter is associated with increased emergency ambulance dispatches for psychiatric emergencies. Environmental Research, 2019, 177, 108611.	7.5	14
36	Psychostimulant use and the brain. Addiction, 2019, 114, 2065-2077.	3.3	59

#	Article	IF	CITATIONS
37	Circumstances of death of opioid users being treated with naltrexone. Addiction, 2019, 114, 2000-2007.	3.3	6
38	Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication. Psychiatry Research, 2019, 281, 112606.	3.3	16
39	First diagnosis of psychosis in the prison: results from a data-linkage study. BJPsych Open, 2019, 5, e89.	0.7	3
40	Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. EClinicalMedicine, 2019, 16, 81-97.	7.1	91
41	Commentary on Petersen et al. (2019): Development of problematic substance use in the years that follow diagnosis of schizophrenia. Addiction, 2019, 114, 2227-2228.	3.3	0
42	Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia. Drug and Alcohol Dependence, 2019, 204, 107556.	3.2	19
43	Methamphetamine. Neurology, 2019, 93, 13-14.	1.1	5
44	Health of Carers of Young People with Early Psychosis: A Biopsychosocial Approach. Australian Social Work, 2019, 72, 260-273.	1.0	6
45	The effectiveness of the Keeping the Body in Mind Xtend pilot lifestyle program on dietary intake in first-episode psychosis: Two-year outcomes. Obesity Research and Clinical Practice, 2019, 13, 214-216.	1.8	17
46	Psychostimulant Use and Fatal Stroke in Young Adults. Journal of Forensic Sciences, 2019, 64, 1421-1426.	1.6	22
47	Body mass index and fatal stroke in young adults: A national study. Journal of Clinical Forensic and Legal Medicine, 2019, 63, 1-6.	1.0	7
48	Neuropsychological function at first episode in treatment-resistant psychosis: findings from the ĆSOP-10 study. Psychological Medicine, 2019, 49, 2100-2110.	4.5	22
49	Completed Suicide Among Methamphetamine Users: A National Study. Suicide and Life-Threatening Behavior, 2019, 49, 328-337.	1.9	37
50	Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients. Schizophrenia Research, 2018, 199, 367-373.	2.0	34
51	Relationship between the duration of methamphetamine use and psychotic symptoms: A two-year prospective cohort study. Drug and Alcohol Dependence, 2018, 187, 363-369.	3.2	33
52	Clinical and Autopsy Characteristics of Fatal Methamphetamine Toxicity in Australia. Journal of Forensic Sciences, 2018, 63, 1466-1471.	1.6	21
53	Routine screening and related interventions significantly improve the effectiveness of emergency department detection and management of alcohol withdrawal syndrome. EMA - Emergency Medicine Australasia, 2018, 30, 648-653.	1,1	4
54	Methamphetamine use and future risk for Parkinson's disease: Evidence and clinical implications. Drug and Alcohol Dependence, 2018, 187, 134-140.	3.2	51

#	Article	IF	Citations
55	Physical and psychological health of carers of young people with first episode psychosis. Australasian Psychiatry, 2018, 26, 184-188.	0.7	17
56	2-year follow-up: Still keeping the body in mind. Australian and New Zealand Journal of Psychiatry, 2018, 52, 602-603.	2.3	11
57	Amphetamine availability predicts amphetamine-related mental health admissions: A time series analysis. Australian and New Zealand Journal of Psychiatry, 2018, 52, 1050-1056.	2.3	6
58	Early sustained recovery following first episode psychosis: Evidence from the AESOP10 follow-up study. Schizophrenia Research, 2018, 199, 341-345.	2.0	12
59	Coâ€morbid personality disorder in early intervention psychosis clients is associated with greater key worker emotional involvement. Microbial Biotechnology, 2018, 12, 143-152.	1.7	4
60	Clinical Characteristics of Fatal Methamphetamineâ€related Stroke: A National Study. Journal of Forensic Sciences, 2018, 63, 735-739.	1.6	25
61	Is Obesity in Young People With Psychosis a Foregone Conclusion? Markedly Excessive Energy Intake Is Evident Soon After Antipsychotic Initiation. Frontiers in Psychiatry, 2018, 9, 725.	2.6	13
62	A Novel Landscape for Understanding Physical and Mental Health: Body Mapping Research with Youth Experiencing Psychosis. Art/Research International, 2018, 3, 236-261.	0.1	14
63	Fatal Stroke in Pregnancy and the Puerperium. Stroke, 2018, 49, 3050-3053.	2.0	17
64	y-QUIT: Smoking Prevalence, Engagement, and Effectiveness of an Individualized Smoking Cessation Intervention in Youth With Severe Mental Illness. Frontiers in Psychiatry, 2018, 9, 683.	2.6	8
65	Epidemiological Characteristics and Risk Factors of Methamphetamine—Associated Psychotic Symptoms. Frontiers in Psychiatry, 2018, 9, 489.	2.6	15
66	Duration of untreated psychosis and pathway to care in <scp>R</scp> iyadh, <scp>S</scp> audi <scp>A</scp> rabia. Microbial Biotechnology, 2017, 11, 47-56.	1.7	18
67	Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. Psychological Medicine, 2017, 47, 1981-1989.	4.5	200
68	Childhood trauma: psychiatry's greatest public health challenge?. Lancet Public Health, The, 2017, 2, e300-e301.	10.0	46
69	Methamphetamineâ€related psychosis: an opportunity for assertive intervention and prevention. Addiction, 2017, 112, 927-928.	3.3	16
70	Stroke and methamphetamine use in young adults: a review. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 1079-1091.	1.9	103
71	Escalating patterns of emergency health care prior to first admission with amphetamine psychosis: A window of opportunity?. Drug and Alcohol Dependence, 2017, 180, 171-177.	3.2	11
72	Ethnicity and long-term course and outcome of psychotic disorders in a UK sample: The ÆSOP-10 study. British Journal of Psychiatry, 2017, 211, 88-94.	2.8	71

#	Article	IF	CITATIONS
73	Multi-center MRI prediction models: Predicting sex and illness course in first episode psychosis patients. Neurolmage, 2017, 145, 246-253.	4.2	43
74	Study protocol for a systematic review of evidence for lifestyle interventions targeting smoking, sleep, alcohol/other drug use, physical activity, and healthy diet in people with bipolar disorder. Systematic Reviews, 2016, 5, 106.	5.3	9
75	Adversity in childhood linked to elevated striatal dopamine function in adulthood. Schizophrenia Research, 2016, 176, 171-176.	2.0	77
76	Increased prevalence of self-reported psychotic illness predicted by crystal methamphetamine use: Evidence from a high-risk population. International Journal of Drug Policy, 2016, 38, 16-20.	3.3	27
77	Ten-year outcomes in first episode psychotic major depression patients compared with schizophrenia and bipolar patients. Schizophrenia Research, 2016, 176, 417-422.	2.0	23
78	Acute tranquilisation in young people with first-episode psychosis: Let's start low, go slow. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1204-1205.	2.3	1
79	Outcomes following first-episode psychosis – Why we should intervene early in all ages, not only in youth. Australian and New Zealand Journal of Psychiatry, 2016, 50, 1055-1063.	2.3	25
80	Biological and psychosocial risk factors for psychotic major depression. Social Psychiatry and Psychiatric Epidemiology, 2016, 51, 233-245.	3.1	19
81	Diagnostic change 10 years after a first episode of psychosis. Psychological Medicine, 2015, 45, 2757-2769.	4.5	74
82	Ten-Year Outcomes of First-Episode Psychoses in the MRC ÆSOP-10 Study. Journal of Nervous and Mental Disease, 2015, 203, 379-386.	1.0	90
83	Sensory gating deficits in the attenuated psychosis syndrome. Schizophrenia Research, 2015, 161, 277-282.	2.0	11
84	Mortality in Schizophrenia and Other Psychoses: A 10-Year Follow-up of the Ó"SOP First-Episode Cohort. Schizophrenia Bulletin, 2015, 41, 664-673.	4.3	128
85	Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study–ÂCORRIGENDUM. Psychological Medicine, 2014, 44, 2727-2727.	4.5	2
86	Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study. Psychological Medicine, 2014, 44, 2713-2726.	4.5	192
87	Bilateral hippocampal increase following first-episode psychosis is associated with good clinical, functional and cognitive outcomes. Psychological Medicine, 2014, 44, 1279-1291.	4.5	40
88	History of cannabis use is not associated with alterations in striatal dopamine D ₂ /D ₃ receptor availability. Journal of Psychopharmacology, 2012, 26, 144-149.	4.0	57
89	Individualized prediction of illness course at the first psychotic episode: a support vector machine MRI study. Psychological Medicine, 2012, 42, 1037-1047.	4.5	116
90	Reduced mismatch negativity predates the onset of psychosis. Schizophrenia Research, 2012, 134, 42-48.	2.0	119

#	Article	IF	CITATIONS
91	Linear and non-linear associations of symptom dimensions and cognitive function in first-onset psychosis. Schizophrenia Research, 2012, 140, 221-231.	2.0	24
92	Limbic striatal dopamine D2/3 receptor availability is associated with non-planning impulsivity in healthy adults after exclusion of potential dissimulators. Psychiatry Research - Neuroimaging, 2012, 202, 60-64.	1.8	38
93	Criminal offending and distinguishing features of offenders among persons experiencing a first episode of psychosis. Microbial Biotechnology, 2011, 5, 15-23.	1.7	49
94	Lack of progression of brain abnormalities in first-episode psychosis: a longitudinal magnetic resonance imaging study. Psychological Medicine, 2011, 41, 1677-1689.	4.5	53
95	Reliability and Comparability of Psychosis Patients' Retrospective Reports of Childhood Abuse. Schizophrenia Bulletin, 2011, 37, 546-553.	4.3	361
96	Insight, grey matter and cognitive function in first-onset psychosis. British Journal of Psychiatry, 2010, 197, 141-148.	2.8	87
97	Examining evidence for neighbourhood variation in the duration of untreated psychosis. Health and Place, 2010, 16, 219-225.	3.3	25
98	Differing patterns of brain structural abnormalities between black and white patients with their first episode of psychosis. Psychological Medicine, 2010, 40, 1137-1147.	4.5	13
99	Lateral ventricle differences between first-episode schizophrenia and first-episode psychotic bipolar disorder: A population-based morphometric MRI study. World Journal of Biological Psychiatry, 2010, 11, 873-887.	2.6	23
100	LONGITUDINAL CHANGES OF STRUCTURAL BRAIN ASYMMETRY IN PSYCHOSIS AND HEALTHY CONTROLS. Schizophrenia Research, 2010, 117, 341-342.	2.0	0
101	Truth, lies or self-deception? Striatal D2/3 receptor availability predicts individual differences in social conformity. NeuroImage, 2010, 53, 777-781.	4.2	26
102	Acute effect of the anti-addiction drug bupropion on extracellular dopamine concentrations in the human striatum: An [11C]raclopride PET study. NeuroImage, 2010, 50, 260-266.	4.2	29
103	Neuropsychological functioning in first-episode schizophrenia. British Journal of Psychiatry, 2009, 195, 336-345.	2.8	38
104	Economic impact of early intervention in people at high risk of psychosis. Psychological Medicine, 2009, 39, 1617.	4.5	104
105	Dopamine Release in the Human Striatum: Motor and Cognitive Tasks Revisited. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 554-564.	4.3	42
106	Selective deficits in semantic verbal fluency in patients with a first affective episode with psychotic symptoms and a positive history of mania. Bipolar Disorders, 2009, 11, 323-329.	1.9	14
107	The dopaminergic basis of human behaviors: A review of molecular imaging studies. Neuroscience and Biobehavioral Reviews, 2009, 33, 1109-1132.	6.1	150
108	Abnormal P300 in people with high risk of developing psychosis. NeuroImage, 2008, 41, 553-560.	4.2	87

#	Article	IF	CITATIONS
109	Schizophrenia: From developmental deviance to dopamine dysregulation. European Neuropsychopharmacology, 2008, 18, S129-S134.	0.7	119
110	Duration of prodromal phase and severity of volumetric abnormalities in first-episode psychosis. British Journal of Psychiatry, 2007, 191, s123-s127.	2.8	30
111	Grey matter abnormalities in Brazilians with first-episode psychosis. British Journal of Psychiatry, 2007, 191, s117-s122.	2.8	55
112	Foreword: Improved understanding and treatment of schizophrenia. European Neuropsychopharmacology, 2007, 17, v-vi.	0.7	0
113	Risk factors for schizophrenia â€" All roads lead to dopamine. European Neuropsychopharmacology, 2007, 17, S101-S107.	0.7	100
114	Insight in individuals with an At Risk Mental Stateâ ⁺ †. Schizophrenia Research, 2007, 90, 238-244.	2.0	42
115	Duration of untreated psychosis and neuropsychological function in first episode psychosis. Schizophrenia Research, 2007, 95, 103-110.	2.0	58
116	Gray matter abnormalities associated with duration of untreated psychosis. Schizophrenia Research, 2006, 83, 145-153.	2.0	89
117	Duration of untreated psychosis and ethnicity in the ÆSOP first-onset psychosis study. Psychological Medicine, 2006, 36, 239-247.	4.5	64
118	Clinical and social determinants of duration of untreated psychosis in the ÆSOP first-episode psychosis study. British Journal of Psychiatry, 2006, 189, 446-452.	2.8	168
119	Right and left prefrontal transcranial magnetic stimulation at $1\mathrm{Hz}$ does not affect mood in healthy volunteers. BMC Psychiatry, 2002, 2, 1.	2.6	80
120	Depressed mood during pregnancy and after childbirth. BMJ: British Medical Journal, 2001, 323, 1367-1367.	2.3	5
121	Electromagnetic stimulation in psychiatry. Advances in Psychiatric Treatment, 2001, 7, 181-188.	0.5	6